Enxiao Li

3.0k total citations · 1 hit paper
45 papers, 1.2k citations indexed

About

Enxiao Li is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Enxiao Li has authored 45 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 17 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Enxiao Li's work include Lung Cancer Research Studies (10 papers), Genetic factors in colorectal cancer (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). Enxiao Li is often cited by papers focused on Lung Cancer Research Studies (10 papers), Genetic factors in colorectal cancer (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). Enxiao Li collaborates with scholars based in China, United States and Australia. Enxiao Li's co-authors include Yuxian Bai, Linna Wang, Shukui Qin, Jianping Xiong, Jianjun Zou, Zhenggang Ren, Xiaohong Chen, Xiaoli Chai, Xiaoyan Lin and Weijia Fang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Enxiao Li

44 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Shukui Qin, Zhenggang Ren et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Enxiao Li

Since Specialization

Citations

This map shows the geographic impact of Enxiao Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enxiao Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enxiao Li more than expected).

Fields of papers citing papers by Enxiao Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enxiao Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enxiao Li. The network helps show where Enxiao Li may publish in the future.

Co-authorship network of co-authors of Enxiao Li

This figure shows the co-authorship network connecting the top 25 collaborators of Enxiao Li. A scholar is included among the top collaborators of Enxiao Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enxiao Li. Enxiao Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma 2025 ·Clinical Epigenetics ·Yinying Wu, Yangwei Fan, (unknown), (unknown), Yu Shi, Meichen Wang, Jia Wang, (unknown), (unknown), (unknown), Enxiao Li	1
2	Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result. 2024 ·Journal of Clinical Oncology ·(unknown), Yinying Wu, Yangwei Fan, Yu Shi, Meichen Wang, (unknown), Enxiao Li	1
3	Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma 2022 ·Scientific Reports ·Wei Li, Xue Yang, Yuan Deng, Yina Jiang, (unknown), Enxiao Li, Yinying Wu, Juan Ren, Zhenhua Ma, (unknown), H. Liang, Qingyong Ma, Zheng Wu, Zheng Wang	4
4	Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells 2021 ·Journal of Experimental & Clinical Cancer Research ·Yu Shi, Liankang Sun, Rui Zhang, Yuan Hu, Yinying Wu, (unknown), Danfeng Dong, Chen Chen, Zhimin Geng, Enxiao Li, Yangwei Fan	42
5	Potent antitumor activity of novel taxoids in anaplastic thyroid cancer 2021 ·Endocrine ·Meichen Wang, Changwei Wang, Chao Feng, (unknown), Huan Chen, Bing Liu, Enxiao Li, Wei Liu, (unknown), Iwao Ojima, Peng Hou	3
6	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial breakdown → 2020 ·The Lancet Oncology ·Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaohong Chen, Enxiao Li, Linna Wang, Chunxia Chen, Jianjun Zou	418
7	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 2019 ·Lung Cancer ·Yi‐Long Wu, Caicun Zhou, Shun Lü, Shukui Qin, Hongming Pan, Gang Wu, Ying Cheng, Xiaoqing Liu, Baohui Han, Yunzhong Zhu, Zhaoyang Zhong, Cheng Huang, Lei Chen, Houjie Liang, Enxiao Li, Guoliang Jiang	11
8	Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells 2019 ·Journal of Cancer ·Yangwei Fan, Ke Ma, (unknown), Chuying Wang, Yuan Hu, Yu Shi, Enxiao Li, Qianqian Geng	14
9	Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression 2018 ·Breast Cancer Research ·Chuying Wang, Feng Bai, (unknown), (unknown), Enxiao Li, Xin‐Hai Pei	19
10	Tumor location as a novel high risk parameter for stage II colorectal cancers 2017 ·PLoS ONE ·Biyuan Wang, Jiao Yang, Shuting Li, Meng Lv, Zheling Chen, Enxiao Li, Min Yi, (unknown), (unknown)	24
11	PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma 2017 ·Oncology Letters ·Ke Ma, Xin Wei, (unknown), Yinying Wu, Qianqian Geng, Enxiao Li	50
12	Incidence and survival differences in esophageal cancer among ethnic groups in the United States 2017 ·Oncotarget ·Zheling Chen, (unknown), Xianglin L. Du, Jiao Yang, Yanwei Shen, Shuting Li, (unknown), Meng Lv, (unknown), Enxiao Li, Wei Li, Peijun Liu, Jin Yang, Min Yi	44
13	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors 2016 ·OncoTargets and Therapy ·Yangwei Fan, Ke Ma, Chuying Wang, Jing Ning, Yuan Hu, Danfeng Dong, (unknown), Qianqian Geng, Enxiao Li, Yinying Wu	45
14	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells 2016 ·Neoplasia ·(unknown), Ester Fernández‐Salas, Enxiao Li, Shaomeng Wang	56
15	Knockdown of RHOC by shRNA suppresses invasion and migration of cholangiocellular carcinoma cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal transition 2016 ·Molecular Medicine Reports ·Haixia Yang, Jun Liang, (unknown), (unknown), Ke Ma, Yangwei Fan, Jing Ning, Chuying Wang, Xin Wei, Enxiao Li	24
16	Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer 2016 ·PLoS ONE ·(unknown), Xianglin L. Du, (unknown), Peijun Liu, Shuting Li, Jiao Yang, Meng Lv, (unknown), Xin Wang, Enxiao Li, (unknown), (unknown), Min Yi	9
17	Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways 2016 ·Oncology Reports ·Ke Ma, Chuying Wang, Qianqian Geng, Yangwei Fan, Jing Ning, Haixia Yang, (unknown), (unknown), (unknown), Xin Wei, Enxiao Li, Yinying Wu	3
18	Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study 2015 ·Scientific Reports ·Xiaowen Ma, Yang Song, Kuo Zhang, Lei Shang, Yuan Gao, Wei Zhang, Xiaochang Xue, Huimin Jia, Jian Geng, Wei Zhou, (unknown), Enxiao Li, Xinyu Ti, (unknown), Yingqi Zhang, (unknown)	10
19	Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor 2014 ·Molecular and Clinical Oncology ·Haixia Yang, (unknown), Xin Wei, Fan Wang, Huadong Zhao, Enxiao Li	9
20	Expression and prognostic relevance of Cyclophilin A and matrix metalloproteinase 9 in esophageal squamous cell carcinoma 2013 ·Diagnostic Pathology ·Yi Li, Hui Guo, Danfeng Dong, Huili Wu, Enxiao Li	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact